News | August 30, 2025
Lilly's Verzenio scores first OS improvement in breast Cancer
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Rivaroxaban is used to treat venous thromboembolism
Subscribe To Our Newsletter & Stay Updated
